Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Letter to the Editor: Response to Vermont Talc-miners Cohort Study Update.

Egilman D, Madigan D, Yimam M, Tran T.

J Occup Environ Med. 2019 Nov 19. doi: 10.1097/JOM.0000000000001783. [Epub ahead of print] No abstract available.

PMID:
31790061
2.

The marketing of OxyContin®: A cautionary tale.

Egilman DS, Collins GDYCB, Falender J, Shembo N, Keegan C, Tohan S.

Indian J Med Ethics. 2019 Jul-Sept;4(3):183-193. doi: 10.20529/IJME.2019.043.

3.

Talc, Asbestos, and Epidemiology: Corporate Influence and Scientific Incognizance.

Tran TH, Steffen JE, Clancy KM, Bird T, Egilman DS.

Epidemiology. 2019 Nov;30(6):783-788. doi: 10.1097/EDE.0000000000001091. No abstract available.

4.

Response to Paustenbach.

Egilman D.

Am J Ind Med. 2019 Jul;62(7):627-630. doi: 10.1002/ajim.23001. Epub 2019 Jun 12. No abstract available.

PMID:
31187510
5.

Letter to the editor on " Survivorship of a modular acetabular cup system: medium- to long-term follow-up".

Egilman DS, Steffen JE, Fassler EA, Reardon KJ.

Arthroplast Today. 2018 Aug 6;4(3):392-393. doi: 10.1016/j.artd.2018.05.006. eCollection 2018 Sep. No abstract available.

6.

Use of Anti-Warnings to Falsely Reassure Downstream Users: An Asbestos Example.

Egilman D, Bird T, Wilson R.

New Solut. 2018 Nov;28(3):515-538. doi: 10.1177/1048291118794198. Epub 2018 Aug 20. Review.

PMID:
30126335
7.

Commentary on "Assessment of Health Risk From Historical Use of Cosmetic Talcum Powder".

Egilman D, Steffen J.

New Solut. 2018 Nov;28(3):400-409. doi: 10.1177/1048291118794166. Epub 2018 Aug 19.

PMID:
30122133
8.

The Production of Corporate Research to Manufacture Doubt About the Health Hazards of Products: An Overview of the Exponent Bakelite® Simulation Study.

Egilman D.

New Solut. 2018 Aug;28(2):179-201. doi: 10.1177/1048291118765485. Epub 2018 Apr 30. Review.

PMID:
29712511
9.

Correspondence regarding the article "The asbestos fibre burden in human lungs: new insights into the chrysotile debate".

Oliver LC, Belpoggi F, Budnik LT, Egilman D, Frank AL, Mandrioli D, Soskolne CL, Terracini B, Welch L, Baur X.

Eur Respir J. 2017 Dec 21;50(6). pii: 1701644. doi: 10.1183/13993003.01644-2017. Print 2017 Dec. No abstract available.

10.

Grave fraudulence in medical device research: a narrative review of the PIN seeding study for the Pinnacle hip system.

Steffen JE, Fassler EA, Reardon KJ, Egilman DS.

Account Res. 2018;25(1):37-66. doi: 10.1080/08989621.2017.1405259.

PMID:
29258356
11.

Response to Hessel.

Egilman D.

Am J Ind Med. 2017 Oct;60(10):915-920. doi: 10.1002/ajim.22773. No abstract available.

PMID:
28925565
12.

Asbestos, asbestosis, and cancer: The Helsinki criteria for diagnosis and attribution. Critical need for revision of the 2014 update.

Baur X, Woitowitz HJ, Budnik LT, Egilman D, Oliver C, Frank A, Soskolne CL, Landrigan PJ, Lemen RA.

Am J Ind Med. 2017 May;60(5):411-421. doi: 10.1002/ajim.22709. No abstract available.

PMID:
28409857
13.

Corporate corruption of science-Another asbestos example.

Egilman D, Monárrez R.

Am J Ind Med. 2017 Feb;60(2):152-162. doi: 10.1002/ajim.22686.

PMID:
28079278
14.

Unreliable proposed 'new standard' for assessing asbestos exposure.

Egilman D, Baur X, Soskolne CL.

Occup Environ Med. 2016 Oct;73(10):709. doi: 10.1136/oemed-2016-103704. Epub 2016 Jul 27. No abstract available.

PMID:
27466612
15.

A commentary on Roggli's "The So-Called Short-Fiber Controversy".

Egilman D, Tran T.

Int J Occup Environ Health. 2016 Jul;22(3):181-186. doi: 10.1080/10773525.2016.1153866. Epub 2016 May 24.

16.

Short fiber tremolite free chrysotile mesothelioma cohort revealed.

Egilman D, Bird T.

Am J Ind Med. 2016 Mar;59(3):196-9. doi: 10.1002/ajim.22552. Epub 2016 Jan 4.

PMID:
26725926
17.

Ethics, morality, and conflicting interests: how questionable professional integrity in some scientists supports global corporate influence in public health.

Baur X, Budnik LT, Ruff K, Egilman DS, Lemen RA, Soskolne CL.

Int J Occup Environ Health. 2015;21(2):172-5. doi: 10.1179/2049396714Y.0000000103. Epub 2015 Mar 2.

18.

Dust diseases and the legacy of corporate manipulation of science and law.

Egilman D, Bird T, Lee C.

Int J Occup Environ Health. 2014 Apr-Jun;20(2):115-25. doi: 10.1179/1077352514Z.000000000104. Epub 2014 Mar 4.

19.

Workers and consumers should not be exposed to chemicals that have not been tested for toxicity.

Egilman DS.

Am J Ind Med. 2014 Aug;57(8):970-1. doi: 10.1002/ajim.22343. Epub 2014 Jun 25. No abstract available.

PMID:
24965179
20.

Egilman and Schilling respond.

Egilman D, Schilling JH.

Int J Occup Environ Health. 2014 Jan-Mar;20(1):6-8. No abstract available.

21.

MetLife and its corporate allies: dust diseases and the manipulation of science.

Egilman DS, Bird T, Lee C.

Int J Occup Environ Health. 2013 Oct-Dec;19(4):287-303.

PMID:
24588035
22.

Commentary on 'evaluation of take home (para-occupational) exposure to asbestos and disease: a review of the literature', Donovan et al.1.

Egilman DS, Druar NM.

Int J Occup Environ Health. 2013 Jul-Sep;19(3):163-8. doi: 10.1179/1077352513Z.00000000072. No abstract available.

PMID:
23885770
23.

The importance of scientific debate.

Egilman DS.

Int J Occup Environ Health. 2013 Jul-Sep;19(3):157-9. doi: 10.1179/1077352513Z.00000000076. No abstract available.

PMID:
23885768
24.

Statement in response to asbestos industry efforts to prevent a ban on asbestos in Pakistan: chrysotile asbestos use is not safe and must be banned.

Aguilar Madrid G, Beaudry M, Bell W, Bowes D, Brophy J, Burdorf A, Carlsten C, Castleman B, Chaturvedi S, Conti ME, Corra L, Corrêa Filho HR, Cranor CF, Cullen E, Dalvie A, Dickson RC, Digon A, Egilman D, Eisner Falvo C, Fischer E, Frank AL, Frank E, Gee D, Giannasi F, Goldstein BD, Greenberg M, Guidotti TL, Harris WA, Hindry M, Houlson A, Hu H, Huff J, Infante PF, Thambyappa J, Juarez Perez CA, Jeebhay MF, Joshi TK, Keith M, Keyserlingk JR, Khatter K, King D, Kodeih N, Kristensen J, Kulsomboon V, Landrigan PJ, Lee CW, Leigh J, Lemen RA, Lippman A, London L, Matzopoulos R, McCulloch J, McDiarmid MA, Mehrdad R, Mirabelli D, Moshammer H, Notebaert É, Nycz Z, Oberta AF, O'Connor J, O'Neill R, Orris P, Ozonoff D, Paek D, Rickard C, Rodriguez EJ, Sass J, Sentes KE, Simpson IM, Soffritti M, Soskolne CL, Sparling SP, Spiegel J, Takahashi K, Takaro TK, Terracini B, Thébaud-Mony A, Trosic I, Turcotte F, Vakil C, Van Der Walt A, Waterman YR, Watterson A, Wegman DH, Welch LS, Weiss SH, Winston R, Yassi A.

Arch Environ Occup Health. 2013;68(4):243-9. doi: 10.1080/19338244.2013.780807. No abstract available.

PMID:
23697697
25.

Bronchiolitis obliterans and consumer exposure to butter-flavored microwave popcorn: a case series.

Egilman DS, Schilling JH.

Int J Occup Environ Health. 2012 Jan-Mar;18(1):29-42.

PMID:
22550695
26.

Spin your science into gold: direct to consumer marketing within social media platforms.

Egilman D, Druar NM.

Work. 2012;41 Suppl 1:4494-502. doi: 10.3233/WOR-2012-0751-4494. Review.

PMID:
22317414
27.

Report of a recent "brake" through in the fiber burden-mesothelioma dialogue.

Egilman D.

Inhal Toxicol. 2012;24(2):136-7. doi: 10.3109/08958378.2011.643932. No abstract available.

PMID:
22283446
28.

Letter to the Editor regarding the Donovan et al. (2011) article.

Egilman D, Schilling JH.

Crit Rev Toxicol. 2012 Feb;42(2):169-72; author reply 173-83. doi: 10.3109/10408444.2011.651011. No abstract available.

PMID:
22276592
29.

Deconstructing a state-of-the-art review of the asbestos brake industry.

Egilman DS, Ardolino EL, Howe S, Bird T.

New Solut. 2011;21(4):545-71. doi: 10.2190/NS.21.4.e.

PMID:
22202589
30.
31.

Medical schools in sub-Saharan Africa.

De Maeseneer J, Egilman D, Burdick WP, Kaufman A.

Lancet. 2011 Oct 8;378(9799):1294; author reply 1295. doi: 10.1016/S0140-6736(11)61570-5. No abstract available.

PMID:
21982093
32.

Tackling NCDs: a different approach is needed.

De Maeseneer J, Roberts RG, Demarzo M, Heath I, Sewankambo N, Kidd MR, van Weel C, Egilman D, Boelen C, Willems S.

Lancet. 2012 May 19;379(9829):1860-1. doi: 10.1016/S0140-6736(11)61135-5. Epub 2011 Sep 5. No abstract available.

PMID:
21899880
33.

Study of neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trial.

Krumholz SD, Egilman DS, Ross JS.

Arch Intern Med. 2011 Jun 27;171(12):1100-7. doi: 10.1001/archinternmed.2011.241.

34.

An elaboration of "proof" of peritoneal mesothelioma from tremolite free chrysotile.

Egilman D.

Am J Ind Med. 2011 Aug;54(8):647. doi: 10.1002/ajim.20975. Epub 2011 Jun 10. No abstract available.

PMID:
21671249
35.

Corporate versus public interests: community responsibility to defend scientific integrity.

Egilman DS, Druar NM.

Int J Occup Environ Health. 2011 Apr-Jun;17(2):181-5. No abstract available.

PMID:
21618951
36.

A proposal for a safe exposure level for diacetyl.

Egilman DS, Schilling JH, Menendez L.

Int J Occup Environ Health. 2011 Apr-Jun;17(2):122-34.

PMID:
21618944
37.

Small is not necessarily beautiful.

Egilman DS, Bohme S.

Int J Occup Environ Health. 2010 Oct-Dec;16(4):542-3. No abstract available.

PMID:
21222395
38.

Persistence of cardiovascular risk after rofecoxib discontinuation.

Ross JS, Madigan D, Konstam MA, Egilman DS, Krumholz HM.

Arch Intern Med. 2010 Dec 13;170(22):2035-6. doi: 10.1001/archinternmed.2010.461. No abstract available. Erratum in: Arch Intern Med. 2011 Feb 28;171(4):305.

39.

A case of occupational peritoneal mesothelioma from exposure to tremolite-free chrysotile in Quebec, Canada: A black swan case.

Egilman D, Menéndez LM.

Am J Ind Med. 2011 Feb;54(2):153-6. doi: 10.1002/ajim.20882. Epub 2010 Aug 18.

PMID:
20721899
40.

Scientists appeal to Quebec Premier Charest to stop exporting asbestos to the developing world.

Takaro TK, Davis D, Van Rensburg SJ, Arroyo Aguilar RS, Algranti E, Bailar JC 3rd, Belpoggi F, Berlin M, Bhattacharya S, Bonnier Viger YV, Brophy J, Bustinza R, Cameron RB, Dement JM, Egilman D, Castleman B, Chaturvedi S, Cherniack M, Choudhury H, Demers PA, Digangi J, Digon A, Edwards JG, Englund A, Erikson B, Corréa Filho HR, Franco G, Frank AL, Freund A, Gee D, Giordano A, Gochfeld M, Gilberg M, Goldsmith DF, Goldstein BD, Grandjean P, Greenberg M, Gut I, Harari R, Hindry M, Hogstedt C, Huff J, Infante PF, Järvholm B, Kern DG, Keifer M, Khatter K, Kjuus H, Keith M, Koo LC, Kumar A, LaDou J, Landrigan PJ, Lemen RA, Last JM, Lee CW, Leigh J, Levin SM, Lippman A, Madrid GA, McCulloch J, McDiarmid MA, Merchant JA, Monforton C, Morse T, Muir DC, Mukerjee D, Mulloy KB, Myers J, Nuwayhid I, Orris P, Ozonoff D, Paek D, Patra M, Pelclová D, Pepper L, Poje GV, Rahman Q, Reyes B, Robinson BW, Rodríguez E, Rose C, Rosenman KD, Rosenstock L, Ruchirawat M, Rydzyński K, Schneider J, Silverstein B, Siqueira CE, Slatin C, Soffritti M, Soskoline C, Sparer J, Stayner LT, Takaro TK, Tarkowski S, Teitelbaum DT, Tompa A, Trosic I, Turcotte F, Vilela RA, Waterman YR, Watterson A, Wegman DH, Welch LS, Woitowitz HJ, Yanri Z, Zavariz C.

Int J Occup Environ Health. 2010 Apr-Jun;16(2):241-8. No abstract available.

PMID:
20465068
41.

Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance.

Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM.

Arch Intern Med. 2009 Nov 23;169(21):1976-85. doi: 10.1001/archinternmed.2009.394.

42.

Call for global health-systems impact assessments.

Swanson RC, Mosley H, Sanders D, Egilman D, De Maeseneer J, Chowdhury M, Lanata CF, Dearden K, Bryant M.

Lancet. 2009 Aug 8;374(9688):433-5. doi: 10.1016/S0140-6736(09)61212-5. Epub 2009 Jul 2. No abstract available.

PMID:
19577289
43.

Fiber types, asbestos potency, and environmental causation: a peer review of published work and legal and regulatory scientific testimony.

Egilman D.

Int J Occup Environ Health. 2009 Apr-Jun;15(2):202-28. Erratum in: Int J Occup Environ Health. 2009 Jul-Sep;15(3):248.

PMID:
19496487
44.

Ford, General Motors, Chrysler, asbestos, and a "sane appreciation of the risks".

Egilman D.

Int J Occup Environ Health. 2009 Jan-Mar;15(1):109-10. No abstract available.

PMID:
19267130
45.

Beyond reputation: debate on the role of corporate influence in occupational and environmental medicine.

Bohme SR, Egilman D.

New Solut. 2008;18(3):317-24. doi: 10.2190/NS.18.3.d.

PMID:
18826880
46.

The ADVANTAGE seeding trial: a review of internal documents.

Hill KP, Ross JS, Egilman DS, Krumholz HM.

Ann Intern Med. 2008 Aug 19;149(4):251-8. Review.

PMID:
18711155
47.

IJOEH and the critique of bias.

Egilman DS, Bohme SR.

Int J Occup Environ Health. 2008 Apr-Jun;14(2):147-51. No abstract available.

PMID:
18507293
48.

Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation.

Ross JS, Hill KP, Egilman DS, Krumholz HM.

JAMA. 2008 Apr 16;299(15):1800-12. doi: 10.1001/jama.299.15.1800.

PMID:
18413874
49.

Funding for primary health care in developing countries.

De Maeseneer J, van Weel C, Egilman D, Mfenyana K, Kaufman A, Sewankambo N, Flinkenflögel M.

BMJ. 2008 Mar 8;336(7643):518-9. doi: 10.1136/bmj.39496.444271.80. No abstract available.

50.

Strengthening primary care: addressing the disparity between vertical and horizontal investment.

De Maeseneer J, van Weel C, Egilman D, Mfenyana K, Kaufman A, Sewankambo N.

Br J Gen Pract. 2008 Jan;58(546):3-4. doi: 10.3399/bjgp08X263721. No abstract available.

Supplemental Content

Loading ...
Support Center